世界の長時間作用性β作動薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Long Acting Beta Agonist Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3460
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、95ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、長時間作用性β作動薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（液体、錠剤）、用途別市場規模（病院、診療所、外来手術センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・長時間作用性β作動薬の市場動向
・企業の競争状況、市場シェア
・長時間作用性β作動薬の種類別市場規模（液体、錠剤）
・長時間作用性β作動薬の用途別市場規模（病院、診療所、外来手術センター、その他）
・長時間作用性β作動薬の北米市場規模2016-2027（アメリカ、カナダ）
・長時間作用性β作動薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・長時間作用性β作動薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・長時間作用性β作動薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・長時間作用性β作動薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Sumitomo Dainippon Pharma、AstraZeneca、GlaxoSmithKline、Boehringer Ingelheim International、Mylan、Teva、Merck）
・結論

Long-acting beta-agonists or long-acting beta adrenergic receptor agonists are class of drugs used in the management of asthma by relaxing the muscles surrounding the bronchial tubes and facilitating the opening the airways wider. Long-acting beta-agonists have a longer duration of action of at least 12 hours.

Market Analysis and Insights: Global Long Acting Beta Agonist Market
The global Long Acting Beta Agonist market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Long Acting Beta Agonist market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Long Acting Beta Agonist market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Long Acting Beta Agonist market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Long Acting Beta Agonist market.

Global Long Acting Beta Agonist Scope and Market Size
Long Acting Beta Agonist market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Long Acting Beta Agonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Liquid
Tablet

Segment by Application
Hospitals
Clinics
Ambulatory Surgical Center
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sumitomo Dainippon Pharma
AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim International
Mylan
Teva
Merck

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long Acting Beta Agonist Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Liquid
1.2.3 Tablet
1.3 Market by Application
1.3.1 Global Long Acting Beta Agonist Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Center
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Long Acting Beta Agonist Market Perspective (2016-2027)
2.2 Long Acting Beta Agonist Growth Trends by Regions
2.2.1 Long Acting Beta Agonist Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Long Acting Beta Agonist Historic Market Share by Regions (2016-2021)
2.2.3 Long Acting Beta Agonist Forecasted Market Size by Regions (2022-2027)
2.3 Long Acting Beta Agonist Industry Dynamic
2.3.1 Long Acting Beta Agonist Market Trends
2.3.2 Long Acting Beta Agonist Market Drivers
2.3.3 Long Acting Beta Agonist Market Challenges
2.3.4 Long Acting Beta Agonist Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Long Acting Beta Agonist Players by Revenue
3.1.1 Global Top Long Acting Beta Agonist Players by Revenue (2016-2021)
3.1.2 Global Long Acting Beta Agonist Revenue Market Share by Players (2016-2021)
3.2 Global Long Acting Beta Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Long Acting Beta Agonist Revenue
3.4 Global Long Acting Beta Agonist Market Concentration Ratio
3.4.1 Global Long Acting Beta Agonist Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long Acting Beta Agonist Revenue in 2020
3.5 Long Acting Beta Agonist Key Players Head office and Area Served
3.6 Key Players Long Acting Beta Agonist Product Solution and Service
3.7 Date of Enter into Long Acting Beta Agonist Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Long Acting Beta Agonist Breakdown Data by Type
4.1 Global Long Acting Beta Agonist Historic Market Size by Type (2016-2021)
4.2 Global Long Acting Beta Agonist Forecasted Market Size by Type (2022-2027)

5 Long Acting Beta Agonist Breakdown Data by Application
5.1 Global Long Acting Beta Agonist Historic Market Size by Application (2016-2021)
5.2 Global Long Acting Beta Agonist Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Long Acting Beta Agonist Market Size (2016-2027)
6.2 North America Long Acting Beta Agonist Market Size by Type
6.2.1 North America Long Acting Beta Agonist Market Size by Type (2016-2021)
6.2.2 North America Long Acting Beta Agonist Market Size by Type (2022-2027)
6.2.3 North America Long Acting Beta Agonist Market Size by Type (2016-2027)
6.3 North America Long Acting Beta Agonist Market Size by Application
6.3.1 North America Long Acting Beta Agonist Market Size by Application (2016-2021)
6.3.2 North America Long Acting Beta Agonist Market Size by Application (2022-2027)
6.3.3 North America Long Acting Beta Agonist Market Size by Application (2016-2027)
6.4 North America Long Acting Beta Agonist Market Size by Country
6.4.1 North America Long Acting Beta Agonist Market Size by Country (2016-2021)
6.4.2 North America Long Acting Beta Agonist Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Long Acting Beta Agonist Market Size (2016-2027)
7.2 Europe Long Acting Beta Agonist Market Size by Type
7.2.1 Europe Long Acting Beta Agonist Market Size by Type (2016-2021)
7.2.2 Europe Long Acting Beta Agonist Market Size by Type (2022-2027)
7.2.3 Europe Long Acting Beta Agonist Market Size by Type (2016-2027)
7.3 Europe Long Acting Beta Agonist Market Size by Application
7.3.1 Europe Long Acting Beta Agonist Market Size by Application (2016-2021)
7.3.2 Europe Long Acting Beta Agonist Market Size by Application (2022-2027)
7.3.3 Europe Long Acting Beta Agonist Market Size by Application (2016-2027)
7.4 Europe Long Acting Beta Agonist Market Size by Country
7.4.1 Europe Long Acting Beta Agonist Market Size by Country (2016-2021)
7.4.2 Europe Long Acting Beta Agonist Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Long Acting Beta Agonist Market Size (2016-2027)
8.2 Asia-Pacific Long Acting Beta Agonist Market Size by Type
8.2.1 Asia-Pacific Long Acting Beta Agonist Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Long Acting Beta Agonist Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Long Acting Beta Agonist Market Size by Type (2016-2027)
8.3 Asia-Pacific Long Acting Beta Agonist Market Size by Application
8.3.1 Asia-Pacific Long Acting Beta Agonist Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Long Acting Beta Agonist Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Long Acting Beta Agonist Market Size by Application (2016-2027)
8.4 Asia-Pacific Long Acting Beta Agonist Market Size by Region
8.4.1 Asia-Pacific Long Acting Beta Agonist Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Long Acting Beta Agonist Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Long Acting Beta Agonist Market Size (2016-2027)
9.2 Latin America Long Acting Beta Agonist Market Size by Type
9.2.1 Latin America Long Acting Beta Agonist Market Size by Type (2016-2021)
9.2.2 Latin America Long Acting Beta Agonist Market Size by Type (2022-2027)
9.2.3 Latin America Long Acting Beta Agonist Market Size by Type (2016-2027)
9.3 Latin America Long Acting Beta Agonist Market Size by Application
9.3.1 Latin America Long Acting Beta Agonist Market Size by Application (2016-2021)
9.3.2 Latin America Long Acting Beta Agonist Market Size by Application (2022-2027)
9.3.3 Latin America Long Acting Beta Agonist Market Size by Application (2016-2027)
9.4 Latin America Long Acting Beta Agonist Market Size by Country
9.4.1 Latin America Long Acting Beta Agonist Market Size by Country (2016-2021)
9.4.2 Latin America Long Acting Beta Agonist Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Long Acting Beta Agonist Market Size (2016-2027)
10.2 Middle East & Africa Long Acting Beta Agonist Market Size by Type
10.2.1 Middle East & Africa Long Acting Beta Agonist Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Long Acting Beta Agonist Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Long Acting Beta Agonist Market Size by Type (2016-2027)
10.3 Middle East & Africa Long Acting Beta Agonist Market Size by Application
10.3.1 Middle East & Africa Long Acting Beta Agonist Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Long Acting Beta Agonist Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Long Acting Beta Agonist Market Size by Application (2016-2027)
10.4 Middle East & Africa Long Acting Beta Agonist Market Size by Country
10.4.1 Middle East & Africa Long Acting Beta Agonist Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Long Acting Beta Agonist Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sumitomo Dainippon Pharma
11.1.1 Sumitomo Dainippon Pharma Company Details
11.1.2 Sumitomo Dainippon Pharma Business Overview
11.1.3 Sumitomo Dainippon Pharma Long Acting Beta Agonist Introduction
11.1.4 Sumitomo Dainippon Pharma Revenue in Long Acting Beta Agonist Business (2016-2021)
11.1.5 Sumitomo Dainippon Pharma Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Long Acting Beta Agonist Introduction
11.2.4 AstraZeneca Revenue in Long Acting Beta Agonist Business (2016-2021)
11.2.5 AstraZeneca Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Long Acting Beta Agonist Introduction
11.3.4 GlaxoSmithKline Revenue in Long Acting Beta Agonist Business (2016-2021)
11.3.5 GlaxoSmithKline Recent Development
11.4 Boehringer Ingelheim International
11.4.1 Boehringer Ingelheim International Company Details
11.4.2 Boehringer Ingelheim International Business Overview
11.4.3 Boehringer Ingelheim International Long Acting Beta Agonist Introduction
11.4.4 Boehringer Ingelheim International Revenue in Long Acting Beta Agonist Business (2016-2021)
11.4.5 Boehringer Ingelheim International Recent Development
11.5 Mylan
11.5.1 Mylan Company Details
11.5.2 Mylan Business Overview
11.5.3 Mylan Long Acting Beta Agonist Introduction
11.5.4 Mylan Revenue in Long Acting Beta Agonist Business (2016-2021)
11.5.5 Mylan Recent Development
11.6 Teva
11.6.1 Teva Company Details
11.6.2 Teva Business Overview
11.6.3 Teva Long Acting Beta Agonist Introduction
11.6.4 Teva Revenue in Long Acting Beta Agonist Business (2016-2021)
11.6.5 Teva Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Long Acting Beta Agonist Introduction
11.7.4 Merck Revenue in Long Acting Beta Agonist Business (2016-2021)
11.7.5 Merck Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Long Acting Beta Agonist Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Liquid
Table 3. Key Players of Tablet
Table 4. Global Long Acting Beta Agonist Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Long Acting Beta Agonist Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Long Acting Beta Agonist Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Long Acting Beta Agonist Market Share by Regions (2016-2021)
Table 8. Global Long Acting Beta Agonist Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Long Acting Beta Agonist Market Share by Regions (2022-2027)
Table 10. Long Acting Beta Agonist Market Trends
Table 11. Long Acting Beta Agonist Market Drivers
Table 12. Long Acting Beta Agonist Market Challenges
Table 13. Long Acting Beta Agonist Market Restraints
Table 14. Global Long Acting Beta Agonist Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Long Acting Beta Agonist Market Share by Players (2016-2021)
Table 16. Global Top Long Acting Beta Agonist Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Long Acting Beta Agonist as of 2020)
Table 17. Ranking of Global Top Long Acting Beta Agonist Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Long Acting Beta Agonist Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Long Acting Beta Agonist Product Solution and Service
Table 21. Date of Enter into Long Acting Beta Agonist Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Long Acting Beta Agonist Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Long Acting Beta Agonist Revenue Market Share by Type (2016-2021)
Table 25. Global Long Acting Beta Agonist Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Long Acting Beta Agonist Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Long Acting Beta Agonist Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Long Acting Beta Agonist Revenue Market Share by Application (2016-2021)
Table 29. Global Long Acting Beta Agonist Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Long Acting Beta Agonist Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Long Acting Beta Agonist Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Long Acting Beta Agonist Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Long Acting Beta Agonist Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Long Acting Beta Agonist Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Long Acting Beta Agonist Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Long Acting Beta Agonist Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Long Acting Beta Agonist Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Long Acting Beta Agonist Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Long Acting Beta Agonist Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Long Acting Beta Agonist Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Long Acting Beta Agonist Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Long Acting Beta Agonist Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Long Acting Beta Agonist Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Long Acting Beta Agonist Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Long Acting Beta Agonist Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Long Acting Beta Agonist Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Long Acting Beta Agonist Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Long Acting Beta Agonist Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Long Acting Beta Agonist Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Long Acting Beta Agonist Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Long Acting Beta Agonist Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Long Acting Beta Agonist Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Long Acting Beta Agonist Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Long Acting Beta Agonist Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Long Acting Beta Agonist Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Long Acting Beta Agonist Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Long Acting Beta Agonist Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Long Acting Beta Agonist Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Long Acting Beta Agonist Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Long Acting Beta Agonist Market Size by Country (2022-2027) & (US$ Million)
Table 61. Sumitomo Dainippon Pharma Company Details
Table 62. Sumitomo Dainippon Pharma Business Overview
Table 63. Sumitomo Dainippon Pharma Long Acting Beta Agonist Product
Table 64. Sumitomo Dainippon Pharma Revenue in Long Acting Beta Agonist Business (2016-2021) & (US$ Million)
Table 65. Sumitomo Dainippon Pharma Recent Development
Table 66. AstraZeneca Company Details
Table 67. AstraZeneca Business Overview
Table 68. AstraZeneca Long Acting Beta Agonist Product
Table 69. AstraZeneca Revenue in Long Acting Beta Agonist Business (2016-2021) & (US$ Million)
Table 70. AstraZeneca Recent Development
Table 71. GlaxoSmithKline Company Details
Table 72. GlaxoSmithKline Business Overview
Table 73. GlaxoSmithKline Long Acting Beta Agonist Product
Table 74. GlaxoSmithKline Revenue in Long Acting Beta Agonist Business (2016-2021) & (US$ Million)
Table 75. GlaxoSmithKline Recent Development
Table 76. Boehringer Ingelheim International Company Details
Table 77. Boehringer Ingelheim International Business Overview
Table 78. Boehringer Ingelheim International Long Acting Beta Agonist Product
Table 79. Boehringer Ingelheim International Revenue in Long Acting Beta Agonist Business (2016-2021) & (US$ Million)
Table 80. Boehringer Ingelheim International Recent Development
Table 81. Mylan Company Details
Table 82. Mylan Business Overview
Table 83. Mylan Long Acting Beta Agonist Product
Table 84. Mylan Revenue in Long Acting Beta Agonist Business (2016-2021) & (US$ Million)
Table 85. Mylan Recent Development
Table 86. Teva Company Details
Table 87. Teva Business Overview
Table 88. Teva Long Acting Beta Agonist Product
Table 89. Teva Revenue in Long Acting Beta Agonist Business (2016-2021) & (US$ Million)
Table 90. Teva Recent Development
Table 91. Merck Company Details
Table 92. Merck Business Overview
Table 93. Merck Long Acting Beta Agonist Product
Table 94. Merck Revenue in Long Acting Beta Agonist Business (2016-2021) & (US$ Million)
Table 95. Merck Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Long Acting Beta Agonist Market Share by Type: 2020 VS 2027
Figure 2. Liquid Features
Figure 3. Tablet Features
Figure 4. Global Long Acting Beta Agonist Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Ambulatory Surgical Center Case Studies
Figure 8. Others Case Studies
Figure 9. Long Acting Beta Agonist Report Years Considered
Figure 10. Global Long Acting Beta Agonist Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Long Acting Beta Agonist Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Long Acting Beta Agonist Market Share by Regions: 2020 VS 2027
Figure 13. Global Long Acting Beta Agonist Market Share by Regions (2022-2027)
Figure 14. Global Long Acting Beta Agonist Market Share by Players in 2020
Figure 15. Global Top Long Acting Beta Agonist Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Long Acting Beta Agonist as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Long Acting Beta Agonist Revenue in 2020
Figure 17. Global Long Acting Beta Agonist Revenue Market Share by Type (2016-2021)
Figure 18. Global Long Acting Beta Agonist Revenue Market Share by Type (2022-2027)
Figure 19. North America Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Long Acting Beta Agonist Market Share by Type (2016-2027)
Figure 21. North America Long Acting Beta Agonist Market Share by Application (2016-2027)
Figure 22. North America Long Acting Beta Agonist Market Share by Country (2016-2027)
Figure 23. United States Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Long Acting Beta Agonist Market Share by Type (2016-2027)
Figure 27. Europe Long Acting Beta Agonist Market Share by Application (2016-2027)
Figure 28. Europe Long Acting Beta Agonist Market Share by Country (2016-2027)
Figure 29. Germany Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Long Acting Beta Agonist Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Long Acting Beta Agonist Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Long Acting Beta Agonist Market Share by Region (2016-2027)
Figure 39. China Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Long Acting Beta Agonist Market Share by Type (2016-2027)
Figure 47. Latin America Long Acting Beta Agonist Market Share by Application (2016-2027)
Figure 48. Latin America Long Acting Beta Agonist Market Share by Country (2016-2027)
Figure 49. Mexico Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Long Acting Beta Agonist Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Long Acting Beta Agonist Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Long Acting Beta Agonist Market Share by Country (2016-2027)
Figure 55. Turkey Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Long Acting Beta Agonist Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Sumitomo Dainippon Pharma Revenue Growth Rate in Long Acting Beta Agonist Business (2016-2021)
Figure 59. AstraZeneca Revenue Growth Rate in Long Acting Beta Agonist Business (2016-2021)
Figure 60. GlaxoSmithKline Revenue Growth Rate in Long Acting Beta Agonist Business (2016-2021)
Figure 61. Boehringer Ingelheim International Revenue Growth Rate in Long Acting Beta Agonist Business (2016-2021)
Figure 62. Mylan Revenue Growth Rate in Long Acting Beta Agonist Business (2016-2021)
Figure 63. Teva Revenue Growth Rate in Long Acting Beta Agonist Business (2016-2021)
Figure 64. Merck Revenue Growth Rate in Long Acting Beta Agonist Business (2016-2021)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

以下、関連資料のご紹介

世界の長時間作用型注射剤市場規模・現状・予測（2021年-2027年）

Global Long-Acting Injectables Market Size, Status and Forecast 2021-2027
QYR2104Z3464 2021年4月 95Pages
QYResearch社発行の本調査資料では、長時間作用型注射剤のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（中・小分子、大分子）、用途別市場規模（統合失調症、その他精神病性障害）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、...

世界のロング・トリプルジャンプ装置市場規模・現状・予測（2021年-2027年）

Global Long and Triple Jump Equipments Market Size, Status and Forecast 2021-2027
QYR2104Z3461 2021年4月 95Pages
QYResearch社発行の本調査資料では、ロング・トリプルジャンプ装置のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（砂場カバー、テイクオフボード、ピットレーキ、その他）、用途別市場規模（アマチュア、プロ）、主要地域別市場規模（北米、アメリカ...

世界のロング・トリプルジャンプ装置市場規模・現状・予測（2021年-2027年）

世界の長距離レーダーシステム市場規模・現状・予測（2021年-2027年）

Global Long Radar System Market Size, Status and Forecast 2021-2027
QYR2104Z3462 2021年4月 99Pages
QYResearch社発行の本調査資料では、長距離レーダーシステムのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（CWレーダー、パルスレーダー）、用途別市場規模（防衛、商業、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本...

世界の長期療養市場規模・現状・予測（2021年-2027年）

Global Long-Term Care Market Size, Status and Forecast 2021-2027
QYR2104Z3465 2021年4月 98Pages
QYResearch社発行の本調査資料では、長期療養のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（在宅医療、病院、介護、生活支援施設）、用途別市場規模（病院、ナーシングホーム、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジ...

世界の長期療養市場規模・現状・予測（2021年-2027年）

世界の介護＆在宅医療用技術市場規模・現状・予測（2021年-2027年）

Global Technologies for Long-Term Care and Home Healthcare Market Size, Status and Forecast 2021-2027
QYR2104Z5567 2021年4月 93Pages
QYResearch社発行の本調査資料では、介護＆在宅医療用技術のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（遠隔医療技術、安全監視技術）、用途別市場規模（病院、ナーシングホーム、家庭用、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッ...

世界のロング・ターム・ケア・プロバイダー市場規模・現状・予測（2021年-2027年）

Global Long Term Care Provider Market Size, Status and Forecast 2021-2027
QYR2104Z3463 2021年4月 96Pages
QYResearch社発行の本調査資料では、ロング・ターム・ケア・プロバイダーのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（在宅医療、病院、介護、生活支援施設）、用途別市場規模（女性、男性）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、ア...

世界のオピオイドアゴニスト薬市場 2021：企業別、地域別、種類・用途別

Global Opioids Agonist Drugs Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-2104Z10261 2021年4月 101Pages
当調査資料では、オピオイドアゴニスト薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。オピオイドアゴニスト薬の種類別市場規模（コデイン、フェンタニル、メペリジン、メタドン、モルヒネ、ヒドロコドン）、用途別市場規模（痛み管理、咳治療、下痢治療）、地域別市...

世界のCISインスリン市場規模・現状・予測（2021年-2027年）

Global CIS Insulin Market Size, Status and Forecast 2021-2027
QYR2104Z1344 2021年4月 93Pages
QYResearch社発行の本調査資料では、CISインスリンのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（長時間作用型アナログ、速効型アナログ、プレミックスアナログ、中間インスリン、短時間作用型インスリン、プレミックスインスリン）、用途別市場...

世界の長時間作用型注射剤市場規模・現状・予測（2021年-2027年） Long-acting injectable (LAI) is a kind of pharmaceutical for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication. Rather than the daily pill-taking required with oral antipsychotics, LAI antipsychotics are administered by injection at two to four weeks in…
世界のオピオイドアゴニスト薬市場 2021：企業別、地域別、種類・用途別 The Opioids Agonist Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulatio…
世界のロング・トリプルジャンプ装置市場規模・現状・予測（2021年-2027年） The triple jump, sometimes referred to as the hop, step and jump or the hop, skip and jump, is a track and field event, similar to the long jump. Long and Triple Jump Equipments are sport devices that used in the long and triple jump. Market Analysis and Insights: Global Long and Triple Jump Equipme…
世界のロング・トリプルジャンプ装置市場規模・現状・予測（2021年-2027年） The triple jump, sometimes referred to as the hop, step and jump or the hop, skip and jump, is a track and field event, similar to the long jump. Long and Triple Jump Equipments are sport devices that used in the long and triple jump. Market Analysis and Insights: Global Long and Triple Jump Equipme…
世界の長距離レーダーシステム市場規模・現状・予測（2021年-2027年） Radar is an object-detection system that uses radio waves to determine the range, angle, or velocity of objects. Market Analysis and Insights: Global Long Radar System Market The global Long Radar System market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR…